Curetis : Press Release 08/2017

The conference call will be supplemented by a presentation, which can be accessed during the call at ht t p: // www. curet is. com / en/ investor s/f inancial - r eports- and- conf er ences/f inancial-

r eport s. ht m l.

For participating in the earnings conference call, please access the presentation at

htt p: // www. audio- webcas t . com / using the passcode curetis0817.

To access the call, please dial the following numbers using the passcode 93120684# Belgium: +32 11500307

Germany: +49 69222229043

Netherlands: +31 107137273

UK: +44 2030092452

U.S.: +1 855 4027766

Further country-specific dial-in numbers can be found at

htt p: // event s. ark adin.com / ev/ docs/ I nt ernat ional Access Number s_ UKFELBRI 1_SU7.pdf

The full first half-year report 2017 will be available as of August 16, 2017, at

htt p: // www. curet is. com/ en/investor s/f inancial - r epor t s- and - conf erences/f inancial- r eports. ht m l

The live webcast and a replay will be available at htt p: // curet is160817- live.audio-

webcast. com.

###

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.

In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Curetis

Max-Eyth-Str. 42

71088 Holzgerlingen, Germany

Tel. +49 7031 49195-10

pr@cur et is. com orir @cur etis.com

w ww.curet i s. com -w w w.unyvero.com

akampion

Dr. Ludger Wess / Ines-Regina Buth Managing Partners info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

The Ruth Group Lee Roth

lroth@theruthgroup.com Tel. +1 646 536 7012